ESPERION THERAPEUTICS Executives Sell Over 75% of Holdings in Routine Tax‑Settled RSU Disposals—No Red Flags Amid Upcoming Merger Flash.

Insider Activity Highlights

On June 17, 2026, Chief Legal Officer Looker Benjamin executed a sale of 11,824 shares of ESPERION THERAPEUTICS common stock at $3.16 per share. The transaction was a tax‑settlement sale of vested Restricted Stock Units (RSUs), a common practice for executives when equity awards mature. While the sale itself is routine, the timing coincides with a broader wave of insider selling by the company’s top leadership—including President & CEO Sheldon Koenig (53,588 shares) and CFO Benjamin Halladay (10,773 shares). Together, these moves reduced the cumulative holdings of the three senior executives by over 75 % from the peak of 2.4 million shares.

Implications for Investors

The pattern of recent sales suggests a short‑term liquidity need rather than a signal of diminished confidence. The share price, hovering just above $3.17, has shown modest monthly gains (0.64 %) but remains volatile—tracing a 52‑week range of $0.95 to $4.18. The negative P/E of –94.33 reflects the company’s heavy investment in research and the impending merger with Essence Parent Inc., which could unlock substantial value once the deal closes. For investors, the insider sales could be viewed as a neutral event: executives are selling RSU shares to cover taxes, not to divest equity in anticipation of a downturn.

Profile of Looker Benjamin

Looker Benjamin’s transaction history demonstrates a disciplined approach to equity management. Since March 2026, the officer has accumulated roughly 685,000 shares via a mix of stock options and outright purchases, and has sold a cumulative 27,000 shares in 2025–2026. The majority of his sales have been modest, often aligning with the vesting schedule of RSUs. Unlike the CEO and CFO, whose sales are more frequent and sizable, Benjamin’s activity reflects a focus on maintaining a balanced equity stake while meeting tax obligations. His recent sale on June 17 fits this pattern, reinforcing the view that the officer is not divesting in anticipation of adverse news.

Future Outlook

With the merger with Essence Parent Inc. expected to close soon, ESPERION’s share price could see a rally if the deal is approved. Investors should monitor the virtual shareholder meeting on July 8 for confirmation. Meanwhile, the insider activity—particularly the tax‑related sales—does not raise immediate red flags. Instead, it underscores a typical executive behavior: exercising vested awards and managing tax liabilities while maintaining a long‑term equity position in a biotech firm poised for significant structural change.